Dr. Kamdar is a Partner with Domain Associates, a healthcare venture capital leader. With a background in small molecule drug discovery, she has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine. Dr. Kamdar is currently Chair of the Board of Directors of Obalon Therapeutics and serves on the boards of Epic Sciences, Evofem Biosciences, Omniome and Sera Prognostics. She is also a board member of San Diego’s CONNECT Foundation and an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine.

Dr. Kamdar is the author of 10 papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in Biochemistry and Genetics from Emory University.

Mr. Gupta is a Partner at Wittington Ventures, a Toronto-based venture capital firm, where he focuses on the future of healthcare. As an operator and investor, he has spent his career at the intersection of technology and investing. Mr. Gupta was the former Global Head of Strategy and Corporate Development at Element AI, where he led their $150M Series B. Prior to that, he was an investor at OMERS Ventures, where he developed an investment thesis around commercializing applications of AI. Mr. Gupta was an early member of Torstar Digital, the corporate venture and innovation arm for Torstar, where he acquired and incubated a portfolio of more than ten digital businesses.

Mr. Gupta received an M.B.A from the Kellogg School of Management and an H.B.A. from the Richard Ivey School of Business. He holds a C.P.A. accounting designation.

Mr. Krishnamurthi is Managing Partner at Greatpoint Ventures, a California-based venture capital firm. A serial entrepreneur and investor, Mr. Krishnamurthi is focused on enterprise IT, and the intersection of computer science and life sciences. He founded two medical related companies – CAPP Medical, a liquid biopsy company for cancer diagnosis (sold to Roche Diagnostics), and CiberMed which focuses on biomarker discovery. He is currently a Board member of Activ Surgical, EVEN Financial, Insight-rx, Namogoo, Recogni and Scoredata.

Mr. Krishnamurthi has a B.S. in Electrical Engineering from Manipal Institute of Technology and a M.S. in Computer Engineering from Syracuse University.

Mr. Meister brings over three decades of experience to Truvian’s board, serving in senior executive and board roles for high-growth and publicly traded companies. Most recently, Mr. Meister served as President of MacAndrews & Forbes Incorporated, a private company that owns or controls a diverse set of companies, including Revlon, Scientific Games, Harlan Clarke Corp., and SIGA Technologies. Prior to that role, he was Chairman and CEO of inVentiv Health (now Syneos Health) and Chairman of the Board at Thermo Fisher Scientific. Mr. Meister co-founded Liberty Lane Partners, LLC, a private investment company and Perspecta Trust, a trust company that provides trust and investment services. He is currently Director of the boards at Arbor Biotechnologies, Inc., Core & Main LP, Magnolia Medical Technologies, Inc., PharmaLegacy Laboratories (Shanghai) Co., Ltd., Quanterix Corporation, Revlon, Inc., Scientific Games Corporation and Wheelabrator Technologies Holdings Inc., as well as Vice Chairman at The General Chemical Group.

Mr. Meister holds a B.A. from the University of Michigan and a M.B.A from Northwestern University’s Kellogg School of Management.

Mr. Millon brings decades of experience, expertise and leadership in the healthcare and life science industries to Truvian’s board. He is currently a director at CVS Health, Inc., a role to which he was appointed in 2007 and one that has evolved as a result of the CVS merger with Caremark in April 2007 and Caremark’s purchase of AdvancePCS, a pharmacy benefit management company, in March 2004. Before his post with Caremark, Millon was named to the board of AdvancePCS in 2000 upon the merger of Advance Paradigm and PCS Health Systems. Prior to that, he was president and chief executive officer of PCS from 1996 to 2000, and also served as an executive and held several global leadership positions over the span of two decades with Eli Lilly and Company.

Millon serves on a number of healthcare company boards, including InanoBio Inc., Curemetrix, Equality Health and Valenz, and is also on the advisory boards of several companies, including Sky Republic, Kazuhm and Curematch. The latter two are incubated by Analytics Ventures, where he is also an advisor.

Millon earned a degree in mechanical engineering from Ecole Centrale de Lyon, France, and a degree in economics from the University of Lyon, France. He was awarded a Master’s of Business Administration in finance from the Kellogg School of Management at Northwestern University. He is a trustee of Scottsdale Arts and a board member of ASU Biodesign Institute.

For almost 15 years, Mr. Srinivasan has held executive and management roles at the world’s leading healthcare companies. Prior to joining Truvian, Mr. Srinivasan was Divisional Vice President at Abbott Laboratories, where he was responsible for product software, automation and informatics. Before Abbott, he served as Vice President, Next Generation Platforms for GenMark Diagnostics. Mr. Srinivasan has also held various leadership roles in systems development at Danaher (Beckman Coulter) and Qiagen (Digene). He holds a B.E. in Electrical Engineering from the National Institute of Technology (India), an M.S. in Biomedical Engineering from Drexel University, and an M.B.A. from Northwestern University’s Kellogg School of Management. Mr. Srinivasan currently sits on the Industry Advisory Board for the School of Biomedical Engineering at Colorado State University.

Mr. Tullman is the Executive Chairman and CEO of Transcarent, the first comprehensive, consumer-directed health and care platform for employees of self-insured employers and their families. Born in Silicon Valley, Transcarent’s platform empowers consumers with the kind of information, guidance, and access that leads to better care, better outcomes, and more cost-effective decisions for everyone.

Mr. Tullman is the Founder and former Executive Chairman and CEO of Livongo Health, the first at-scale consumer digital health company to truly empower people with chronic conditions to live better and healthier lives using data science.

In his final year, Mr. Tullman led Livongo through the largest consumer digital health IPO in history, a secondary offering, a convertible debt offering that raised over $550 million, and the industry’s largest merger to date between Livongo and Teladoc Health, valuing Livongo at $18.5 billion and beginning a new era of consumer-centric virtual care.

A visionary leader and entrepreneur, Mr. Tullman previously ran two other public companies that changed the way healthcare is delivered. During his time as CEO of Allscripts, the Company was the leading provider of electronic prescribing, practice management, and electronic health records. Mr. Tullman led Allscripts IPO and Secondary offerings. Prior to Allscripts, he was CEO of Enterprise Systems, which he also took public and then sold to McKesson/HBOC. Before entering healthcare, Mr. Tullman served as President and COO of CCC Information Systems, a provider of computerized systems for the property and casualty insurance sector.

Mr. Tullman is one of two Founding Partners at 7wireVentures, one of the highest-returning venture capital funds in Illinois. He is the author of On Our Terms: Empowering the New Health Consumer, in which he proposes new solutions to address the chronic-condition epidemic facing our country.

Mr. Tullman is dedicated to finding a cure for diabetes and other chronic conditions—and to keeping people healthy until these cures are found. A strong proponent of philanthropy, he was honored in 2019 with a Robert F. Kennedy Human Rights Ripple of Hope Award for his career focused on improving the safety, empathy, and efficiency of our healthcare system. He also serves as a Chancellor to the International Board of the Juvenile Diabetes Research Foundation and as a Board Member of the American Diabetes Association. Mr. Tullman has three amazing children that inspire him every day.

Mr. Wasson is the former President and CEO of Walgreens Boots Alliance, Inc. As President and CEO, he led the Fortune 35 company to record fiscal 2014 sales of $76.4 billion. Mr. Wasson is recognized throughout the drugstore and healthcare industry for transformational leadership, innovation, bold business moves, and executing strategic long-term vision. After retiring, Mr. Wasson founded Wasson Enterprise, a family office that partners to build sustainable, high-growth businesses that do well by doing good. Additionally, he co-founded and is the Chairman of CoolerScreens, an innovative in-store digital marketing and merchandising platform transforming retail point of sale media, and is the Chairman of iA, a leading-edge provider of software enabled pharmacy automation solutions. Mr. Wasson also serves on the boards of Health Care Service Corporation (HCSC), OptimizeRx, Argo Tea, Reliefband, Performance Health Systems, Innventure, The Economic Club of Chicago, Corporate Leadership Center, and AUSL.

Dr. Bethel has nearly 30 years of experience as a practicing pathologist, specializing in diagnosis of blood cancers.  Her research has included investigation of circulating tumor cells in collaboration with researchers at The Scripps Research Institution, the University of Southern California, and the Physical Sciences in Oncology program at the National Institute of Health. She is cofounder and initial laboratory director of Epic Sciences. Additionally, she serves as Chief Medical Officer at Bluestar Genomics.

Dr. Bethel received her BA from Yale University and MD from the George Washington University School of Medicine.

Dr. Abhijit Datta brings over 20 years of medical device/IVD product development and commercialization experience to Truvian. Dr. Datta currently serves as Vice President of Operations and a member of executive management team at Diazyme Laboratories.  Dr. Datta is actively involved in product development and has experience with phase transition of health care products through regulatory cycles and scale up manufacturing in compliance with FDA, Health Canada, NMPA and EU: CE IVD, USDA, DEA and various local and state regulatory authorities.

Dr. Datta was an American Cancer Society Post-Doctoral Fellow at the Dana-Farber Cancer Institute, Harvard University Medical School and the Ludwig Institute of Cancer Research, UCSD, where his work focused on DNA repair, recombination and interactions with cell cycle checkpoint.  He received his master’s degree in Biosciences and Biotechnology from IIT Roorkee, India, and a Biochemistry and Molecular Biology Ph.D. from Emory University where his thesis focused on DNA recombination. Dr. Datta is an author on fifteen scientific publications and inventor on nine granted patents.  Dr. Datta served on board of Diazyme Shanghai, a life science company and serves as an advisor to biotech companies.

Dr. Hoffman attended Columbia University and graduated from Albert Einstein College of Medicine in 2002. He completed his internal medicine residency at the New York University, Langone Medical Center and served an additional year as chief resident. He has worked at Cleveland Clinic in Florida as a hematologist-oncologist and director of the point-of-care lab for chemotherapy patients. In 2009, he moved to the Sylvester Comprehensive Cancer Center at the University of Miami where he works today. At UM, he is an Associate Professor of Clinical Medicine and Associate Director of the heme-oncology fellowship program. He cares for patients and runs clinical trials, particularly for those with plasma cell dyscrasia such as multiple myeloma and amyloidosis. In addition, he teaches the hematology course for its medical school and oversees all heme-oncology curriculum for the four-year program. Dr. Hoffman splits his time between clinical care, research and education.

Dean Kamen is an inventor, an entrepreneur, and a tireless advocate for science and technology. His roles as inventor and advocate are intertwined—his own passion for technology and its practical uses has driven his personal determination to spread the word about technology’s virtues and by so doing to change the culture of the United States.

As an inventor, he holds more than 1000 U.S. and foreign patents, many of them for innovative medical devices that have expanded the frontiers of health care worldwide. While still a college undergraduate, he invented the first wearable infusion pump, which rapidly gained acceptance from such diverse medical specialties as oncology, neonatology, and endocrinology. In 1976, he founded his first medical device company, AutoSyringe, Inc., to manufacture and market the pumps. Then, working with leading diabetes researchers, Dean pioneered the design and adoption of the first portable insulin pump. It was quickly demonstrated that using a pump could much more effectively control patients’ blood glucose levels. At age 30, he sold AutoSyringe to Baxter Healthcare Corporation.

Following the sale of AutoSyringe, Inc., he founded DEKA Research & Development Corporation to develop internally generated inventions as well as to provide research and development for major corporate clients. Kamen led DEKA’s development of the HomeChoiceTM peritoneal dialysis system for Baxter International Inc. The HomeChoiceTM system allows patients to be dialyzed in the privacy and comfort of their home and quickly became the worldwide market leader. Kamen also led the development of technology to improve slide preparation for the CYTYC (now Hologic Inc.) ThinPrep® Pap Test. Kamen-led DEKA teams have also developed critical components of the UVARTM XTSTM System, an extracorporeal photophereisis device marketed by Therakos, a unit of Johnson & Johnson, for treatment of T-Cell lymphoma. An advanced prosthetic arm in development for DARPA should advance the quality of life for returning injured soldiers. Other notable developments include the HydroflexTM surgical irrigation pump for C.R. Bard, the CrownTM stent, an improvement to the original Palmaz-Schatz stent, for Johnson & Johnson, the iBOTTM mobility device, and the Segway® Human Transporter.

Kamen has received many awards for his efforts. Notably, Kamen was awarded the National Medal of Technology in 2000. Presented by President Clinton, this award was in recognition for inventions that have advanced medical care worldwide, and for innovative and imaginative leadership in awakening America to the excitement of science and technology. Kamen was elected a member of the National Academy of Engineering in 1997. He was awarded the Lemelson-MIT Prize in 2002, and was inducted into the National Inventors Hall of Fame in May 2005. He is a Fellow of the American Institute for Medical & Biological Engineering, as well as many other national and international engineering organizations.

Matthew D. Krasowski, MD, PhD brings over 25 years of pathology experience to Truvian. Dr. Krasowski serves as a Clinical Professor, and Vice Chair of Clinical Pathology and Laboratory Services in the Department of Pathology at the University of Iowa Hospitals and Clinics. Dr. Krasowski’s areas of research interest are toxicology and drug monitoring, chemistry assay interferences, laboratory test utilization, pharmacogenetics, immunoassays, and innovative tools for teaching medical students and residents. He has published over 130 peer-reviewed journal articles. Dr. Krasowski obtained his BA from the University of Chicago, PhD in Neurobiology from the University of Chicago and his MD from the University of Chicago.

David Rego brings over 25 years of engineering, operations and manufacturing experience to Truvian’s Scientific Advisory Board. He currently serves as Vice President, Corporate Operations Engineering at Dexcom. Prior to Dexcom, David held numerous technical leadership roles including Director of Manufacturing Engineering for GenMark Diagnostics, VP of Engineering and Strategic Development at CAID Automation and Executive Director of Product Development at SOLON Energy GmbH. Mr. Rego has broad experience in engineering management and organizational development with direct experience in developing and leading complex custom automation projects focused in the medical device and pharmaceutical sector, product development, organizational architecture and implementation. He is the inventor on three patents spanning photovoltaic rooftop modules to medical stents. A licensed professional engineer in Arizona, California and Ontario, Canada, David received his BS in Mechanical Engineering from Queen’s University, Canada.

Dr. Wang brings 15 years of clinical chemistry and point of care testing experience to the Truvian Scientific Advisory board. Dr. Wang is certified by the American Board of Clinical Chemistry in Clinical Chemistry, Molecular Diagnostics and Toxicological Chemistry. Her clinical interests include automation, clinical mass spectrometry and point of care testing. Her research interests focus on novel technologies for precision-based diagnosis and prognosis, especially in the point of care testing field. She currently serves as a Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania and as the Director of the Clinical Chemistry Section and Core Laboratory at University of Pennsylvania Perelman School of Medicine.

Dr. Wang has received a dozen awards and honors including a Career Cornerstone Award and a National Academy of Clinical Biochemistry Distinguished Abstract Award. She has authored about 100 publications and holds numerous patents.  She is principle investigator of many government and industry funded grants and routinely serves on grant study sections and review panels. Dr. Wang received her BS in Biological Sciences & Biotechnology from Tsinghua University, China. She holds a PhD in Molecular and Cellular Pharmacology from the University of Wisconsin-Madison and trained in Clinical Chemistry at the University of California San Francisco.

Dr. Wu is well established in the fields of clinical chemistry, toxicology, cardiac biomarkers and pharmacogenomics. He brings over 30 years of experience to the Truvian Scientific Advisory Board. Dr. Wu previously served as Assistant Professor of Pathology at the University of Texas Medical School, Houston and Associate Director of Clinical Chemistry at Hermann Hospital. He joined Harford Hospital in 1992 to become Director of the Chemistry and Toxicology Laboratories and became Professor of Laboratory Medicine and Adjunct Professor of Chemistry at the University of Connecticut Farmington and Storrs CT campuses, respectively. In 2004, he became Director of Chemistry and Toxicology at San Francisco General Hospital (SFGH) and Professor of Laboratory Medicine at the University of California, San Francisco (UCSF). There, he established the first Clinical Pharmacogenomics Laboratory at UCSF. Dr. Wu currently serves as the Chief of the Clinical Chemistry Laboratory at SFGH and the Chief of Clinical Pharmacogenomics Laboratory at UCSF.Dr. Wu has over 500 peer reviewed and non-peer reviewed publications, book chapters, and books, and hundreds of published abstracts. Since 1999, he has been Editor-in-Chief of Clinica Chimica Acta. He has been the director of COMACC-accredited clinical chemistry postdoctoral program in Texas, Connecticut, and California. He has received numerous awards from the American Association for Clinical Chemistry.

Dr. Wu received his BS in chemistry and biology at Purdue University. He obtained his Ph.D. in Analytical Chemistry from the University of Illinois and is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry.

Dr. Yeo brings over 33 years of clinical chemistry experience to the Truvian Scientific Advisory Board. Dr. Yeo is an academic clinical chemist and is board-certified in Clinical Chemistry (1990) & Toxicological Chemistry (1995) by the American Board of Clinical Chemistry. He was the Director of Clinical Chemistry & Endocrinology Laboratories, Dartmouth Reference Laboratory and Professor of Pathology at Dartmouth-Hitchcock Medical Center (1995-2007). Prior to that he was the Scientific Director of Clinical Chemistry and Endocrinology Laboratories and an Assistant Professor at Beth Israel Hospital & Harvard Medical School (1987-1995). Dr. Yeo was past-President of the Commission on Accreditation in Clinical Chemistry (2017-2018), past-Chair of the AACC Personalized Medicine Division (2017-2018), past Treasurer of the AACC Proteomics & Metabolomics Division (2015-2016), past-Chair of Chicago Section of AACC (2014-2015), past-Chair of the AACC Molecular Pathology Division (2008-2010), and past Vice-President of American Board of Clinical Chemistry (2003-2005). He is currently an Associate Editor (Clinical Chemistry Section) of the American Journal of Clinical Pathology. His research interests are in emerging angiogenic biomarkers, clinical mass spectrometry and clinical pharmacogenomics applications for precision medicine. He had published more than 100 original articles, book chapters and abstracts in the field of clinical chemistry and pharmacogenomics.